Diabetes-Related Dementia

Area of Science:

• Neurology
• Endocrinology
• Geriatrics

Background:

• Type 2 diabetes mellitus (DM) is linked to increased risk of cognitive decline and dementia.
• A distinct dementia subgroup may arise from DM-related metabolic abnormalities, separate from Alzheimer disease (AD) or vascular dementia (VaD).

Purpose of the Study:

• To characterize a specific dementia subgroup associated with type 2 diabetes, termed "diabetes-related dementia" (DrD).
• To differentiate DrD from AD and VaD based on clinical, pathological, and imaging findings.
• To explore potential therapeutic and preventive strategies for DrD.

Main Methods:

• Clinical characterization of patients with DrD, including age, glycemic control (hemoglobin A1c), diabetes duration, insulin use, and apolipoprotein E4 status.
• Neuroimaging (SPECT, MRI) and PET scans (¹¹C-Pittsburgh compound-B) to assess brain perfusion, lesions, atrophy, and amyloid accumulation.
• Assessment of cognitive functions (attention, executive function, word recall) and evaluation of frailty, sarcopenia, and dynapenia.

Main Results:

• DrD presents with specific metabolic abnormalities, often negative amyloid PET scans, and distinct cognitive profiles (impaired attention/executive function, preserved word recall).
• Patients with DrD show less medial temporal lobe atrophy and slower cognitive progression compared to AD.
• Higher frequencies of frailty and sarcopenia/dynapenia are observed in DrD, suggesting the need for geriatric interventions.

Conclusions:

• DrD is a distinct dementia entity associated with type 2 diabetes, characterized by metabolic dysregulation rather than typical AD or VaD pathology.
• Glycemic control, management of insulin resistance, inflammation, oxidative stress, and advanced glycation end products are crucial for cognitive function in DrD.
• DrD is a potentially controllable and modifiable dementia, necessitating specific diagnostic approaches and interventions, including geriatric care.